As the alternate site infusion market expands due to site of care restrictions and clinic visit volumes exceeding demand, it is paramount for home infusion programs to position themselves adequately to capture the specialty opportunity at hand. A large part of this market expansion includes the introduction of newly approved specialty and/or biologic subcutaneous formulations commonly administered in clinic-based settings. Is your home infusion program prepared to seize this opportunity? At this session, we will discuss how to onboard novel subcutaneous injectables, facilitate clinic-administered medication (CAM) to home infusion initiatives, and increase home infusion net revenue generation.
